Natixis Advisors LLC Has $65.46 Million Stake in Zoetis Inc. $ZTS

Natixis Advisors LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 49.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 447,340 shares of the company’s stock after selling 431,642 shares during the period. Natixis Advisors LLC’s holdings in Zoetis were worth $65,455,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC boosted its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the period. Financial Consulate Inc. bought a new position in shares of Zoetis in the third quarter valued at approximately $39,000. SJS Investment Consulting Inc. lifted its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the last quarter. TruNorth Capital Management LLC bought a new position in Zoetis in the 3rd quarter worth $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Zoetis in the 3rd quarter worth $46,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.6%

Shares of ZTS stock opened at $121.54 on Monday. The firm has a fifty day moving average of $126.06 and a 200-day moving average of $132.88. The stock has a market cap of $51.31 billion, a price-to-earnings ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ZTS shares. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.